Biotech | September 18, 2021
Excision receives U.S. FDA clearance for first-in-human CRISPR Phase I/II trail for HIV
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
The goal for the project is the identification and optimization of anti-viral compounds.
Subscribe To Our Newsletter & Stay Updated
